key: cord-0688033-03tozgvp authors: Coomes, Eric A.; Haghbayan, Hourmazd title: Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis date: 2020-08-26 journal: Rev Med Virol DOI: 10.1002/rmv.2141 sha: d1f7c0ef1739c9b2577716821bf526d0292cd934 doc_id: 688033 cord_uid: 03tozgvp Coronaviruses may activate dysregulated host immune responses. As exploratory studies have suggested that interleukin‐6 (IL‐6) levels are elevated in cases of complicated Covid‐19, we undertook a systematic review and meta‐analysis to assess the evidence in this field. We systematically searched MEDLINE and EMBASE for studies investigating the immunological response in Covid‐19; additional grey literature searches were undertaken. Study selection and data abstraction was undertaken independently by two authors. Meta‐analysis was undertaken using random effects models to compute ratios of means with 95% confidence intervals (95%CIs). Eight published studies and two preprints (n = 1798) were eligible for inclusion. Meta‐analysis of mean IL‐6 concentrations demonstrated 2.9‐fold higher levels in patients with complicated Covid‐19 compared with patients with noncomplicated disease (six studies; n = 1302; 95%CI, 1.17‐7.19; I (2) = 100%). Consistent results were found in sensitivity analyses exclusively restricted to studies comparing patients requiring ICU admission vs no ICU admission (two studies; n = 540; ratio of means = 3.24; 95%CI, 2.54‐4.14; P < .001; I (2) = 87%). Nine of ten studies were assessed to have at least moderate risk of bias. In patients with Covid‐19, IL‐6 levels are significantly elevated and associated with adverse clinical outcomes. Inhibition of IL‐6 may be a novel target for therapeutics for the management of dysregulated host responses in patients with Covid‐19 and high‐quality studies of intervention in this field are urgently required. transmission during the presymptomatic incubation period. [11] [12] [13] In China, nearly one-fifth of infected patients experience severe or critical illness, 14 with an overall 2.3% case fatality rate and up to 6.1% of patients experiencing severe complications. 15 Alongside preventative vaccines and antiviral therapies, host-directed therapeutics employing existing immunomodulatory agents must be explored. 16, 17 Coronaviruses have been observed to activate excessive and dysregulated host immune responses which may contribute to the development of acute respiratory distress syndrome (ARDS). 18, 19 Autopsy analyses of patients with Covid-19 complicated by ARDS reveal hyperactivation of cytotoxic T-cells, with high concentrations of cytotoxic granules. 20 Reports describing the immunological profile of critically ill patients with Covid-19 suggest hyperactivation of the humoral immune pathway-including interleukin (IL)-6-as a critical mediator for respiratory failure, shock, and multiorgan dysfunction. Given the potential for the development of cytokine release syndrome (CRS) as pathologic underpinning for disease progression of severe Covid-19, characterizing this dysregulation of host immune responses is important as it may act as a target for therapeutics. We therefore designed a systematic review and meta-analysis to assess the evidence describing IL-6 response in patients with Covid-19 to guide patient diagnosis, clarify the immunogenic profile of Covid-19, and inform future trials targeting this immune mediator. We undertook a systematic review and meta-analysis investigating IL-6 dysregulation in patients diagnosed with Covid-19. Articles eligible for inclusion were observational cohort, case-control, or randomized controlled trials (RCTs) characterizing serum IL-6 dynamics in adult or pediatric patients diagnosed with Covid-19. This systematic review was undertaken with methodology in accordance with Cochrane Handbook, 21 and reporting consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 22 An a priori protocol was designed and registered (PROSPERO identification: CRD42020175879). We designed a high sensitivity search strategy combining free text and keyword search term synonym clusters for Covid-19, combined with clusters for IL-6 or tocilizumab (see Appendix S1 for full search strategies). We then systematically searched for published articles in Ovid MEDLINE and EMBASE and Google Scholar. Further searches were conducted in preprint servers (Biorxiv, Medrxiv, and Chinxiv) employing the keywords "tocilizumab" and "interleukin" to identify potential prepublication manuscripts meeting eligibility criteria. All such searches spanned January 1, 2019 to March 15, 2020. For additional sensitivity, we then conducted a second, expanded, from Google Scholar and the preprint servers were manually parsed for identification of any eligible studies. Reference lists of all included articles were also reviewed for potential eligibility of citations. Results are described and summarized quantitatively and semiqualitatively; for data deemed adequately homogenous in terms of patient characteristics, interventions, and clinical outcomes, metaanalysis was undertaken using random effects models. For statistical homogeneity, medians and IQRs were converted to means with SDs to maximize the number of studies eligible for meta-analysis. 23 For such continuous data, we computed ratio of means (RoM) for each study and undertook meta-analysis via generic inverse variance methods (DerSimonian and Laird) to produce pooled measures of association, corresponding 95% confidence intervals (95%CI), and forest plots. 21 Figure 1 ). An additional two articles were identified via preprint server searches. A total of 10 articles were therefore eligible for inclusion, with 10 (n = 1798) contributing to qualitative synthesis and six (n = 1302) undergoing quantitative synthesis (meta-analysis) (Figure 1) . The remaining four studies (n = 496) were eligible for inclusion but did not present data in a manner permitting the calculation of RoMs and were therefore not pooled in meta-analysis. Individual study characteristics and patient demographics are presented in Table 1 , and inflammatory markers, therapeutic interventions, and disease complications are presented in Table 2 . Ten cohort studies (n = 1798) described the immunological response to SARS-CoV-2 in patients diagnosed with Covid-19; mean age was 54.8 ± 14.4 and 42% were female. All studies were set in China and all but one exclusively recruited hospital inpatients. Of studies reporting the use of immunomodulatory therapies, corticosteroids were the most commonly administered agents and were received by 32% of patients. In studies reporting survival, mortality was 22% among patients diagnosed with Covid-19 (Tables 1 and 2) . Overall, elevations in IL-6 levels among patients with Covid-19 were identified in all included studies. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Multiple studies specifically identified higher levels of IL-6 among patients with more severe (complicated) disease. 29 who survived (11.4 ± 8.5 pg/mL vs 6.8 ± 3.6 pg/mL, P < .001). Risk of bias was assessed via the QUIPS tool in cohort studies assessing inflammatory response in Covid-19. 26, 27 Four studies were determined to be at high risk of bias, 33, 35, 37, 38 five moderate, 29, 31, 32, 34, 36 and one low ( Figure S1 ) 30 ; this was mostly driven by lack of control for confounding and potential inconsistencies in the measurement of the inflammatory mediators under study. In this systematic review and meta-analysis, we demonstrate that serum levels of IL-6 are significantly elevated in the setting of severe Although designed and reported in accordance with standardized systematic review methodology 21, 22 and employing a highly sensitive search strategy, including the grey literature, this study has important limitations, much of which is inherent to the methodological quality of the included primary studies. All primary studies eligible for inclusion were conducted in China, with several studies recruiting participants from the same centres; while none of the included studies described their data as having been previously published, this remains a theoretical possibility. 46 We encountered high levels of statistical heterogeneity in our meta-analysis comparing IL-6 levels between patients with complicated and noncomplicated disease; although we performed prespecified sensitivity analyses, these failed to sufficiently explain this heterogeneity. Such residual heterogeneity may have arisen from multiple sources of variability between studies, most prominently due to likely differences in patient characteristics, lack of consecutive enrolment, variable timing of IL-6 measurement, the absence of a set definition of "supportive care", and differences in adjuvant immunomodulatory medications received, such as corticosteroids and IVIg, which may have affected both IL-6 response and patient outcomes. Most studies included in this review were rated at moderate or high risk of bias, reflecting generally low methodological quality. This was primarily driven by a lack of control for confounding, inconsistencies or lack of clarity of the context in which IL-6 measurements were performed, and potential for selection bias due to lack of consecutive patient enrolment. In this systematic review and meta-analysis, we demonstrate that serum levels of IL-6 are significantly elevated in the setting of complicated Covid-19 disease, and increased IL-6 levels to be in turn significantly associated with adverse clinical outcomes. This suggests that the progression of initial SARS-CoV-2 infection to complicated disease may be the consequence of an excessive host immune response and autoimmune injury. These findings support the need for ongoing controlled clinical studies to elucidate the role of immunomodulation, specifically via IL-6 inhibition, in the therapy of severe A novel coronavirus from patients with pneumonia in China A pneumonia outbreak associated with a new coronavirus of probable bat origin Coronavirus infections-more than just the common cold A novel coronavirus outbreak of global health concern Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV) COVID-19) Situation Report-46. World Health Organization A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Importation and human-tohuman transmission of a novel coronavirus in Vietnam Active monitoring of persons exposed to patients with confirmed COVID-19 -United States Presumed asymptomatic carrier transmission of COVID-19 Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China Clinical characteristics of coronavirus disease 2019 in China Reducing mortality from 2019-nCoV: host-directed therapies should be an option Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Coronavirus infections and immune responses Pathological findings of COVID-19 associated with acute respiratory distress syndrome Cochrane handbook for systematic reviews of interventions version 6.0 (updated) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study Assessing bias in studies of prognostic factors Evaluation of the quality of prognosis studies in systematic reviews ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: a retrospective single center analysis Clinical features of patients infected with 2019 novel coronavirus in Wuhan The potential role of IL-6 in monitoring severe case of coronavirus disease 2019 Dysregulation of immune response in patients with COVID-19 in Wuhan, China Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Reduction and exhaustion of T Cells in patients with coronavirus disease 2019 (COVID-19) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, doubleblind, placebo-controlled, multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or lifethreatening cytokine release syndrome COVID-19: consider cytokine storm syndromes and immunosuppression A systematic review of anakinra, tocilizumab, sarilumab and siltuximab for coronavirus-related infections. medRxiv Interleukin-6 blockade for severe COVID-19. medRxiv Use of in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv Editorial concern-possible reporting of the same patients with COVID-19 in different reports Supporting Information section at the end of this article. How to cite this article: Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and metaanalysis